
Last update at 2026-06-23T19:52:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown |
|---|
| Breakdown |
|---|
| Breakdown |
|---|
Sector: None Industry: None
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LLY Eli Lilly CDR (CAD Hedged) |
0.16 0.40% | 39.78 | 37.91 | 25.77 | 12.03 | 29.35 | 12.92 | 26.57 |
| AVGO Broadcom CDR (CAD Hedged) |
-0.51 3.39% | 14.53 | 12.44 | 5.73 | 4.54 | 3.78 | 28.65 | 52.40 |
| WMT Walmart CDR (CAD Hedged) |
1.02 2.08% | 50.10 | 45.06 | 41.67 | 1.38 | 9.84 | 1.51 | 23.16 |
| JPM JPMorgan CDR (CAD Hedged) |
0.29 0.68% | 42.79 | 14.46 | 14.03 | 4.49 | 2.36 | 6.97 | |
| VISA Visa CDR (CAD Hedged) |
0.12 0.40% | 30.06 | 28.19 | 23.42 | 15.90 | 15.18 | 14.72 | 22.91 |
| Name | Title | Year Born |
|---|---|---|
| Mr. David A. Ricks | Chairman, CEO & President | 1968 |
| Mr. Lucas E. Montarce | Executive VP & CFO | 1977 |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | Chief Scientific & Product Officer and President of Lilly Research Laboratories | 1973 |
| Ms. Anat Hakim J.D. | Executive VP, General Counsel & Secretary | 1969 |
| Mr. Jacob S. Van Naarden | Executive VP & President of Lilly Oncology | 1985 |
| Mr. Gordon Brooks | Group VP, Controller & Corporate Strategy | NA |
| Mr. Donald A. Zakrowski | Senior VP of Finance & Chief Accounting Officer | NA |
| Mr. Diogo Rau | EVP & Chief Information and Digital Officer | 1975 |
| Mr. Eric Dozier | Executive VP & Chief People Officer | 1967 |
| Mr. Jeffrey N. Simmons | Senior VP & President of Elanco Animal Health | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.